References
- Stone NRH , BicanicT, SalimR, HopeW. Liposomal Amphotericin B (AmBisome): A Review of the Pharmacokinetics, Pharmacodynamics, Clinical Experience and Future Directions. Drugs. DOI 10.1007/s40265-016-0538-7.
- US Food and Drug Administration. Liposome drug products, chemistry, manufacturing, and controls; human pharmacokinetics and bioavailability; and labeling documentation, guidance for industry (2018). https://www.fda.gov/media/70837/download
- European Medicines Agency. Committee for Human Medicinal Products (CHMP) reflection paper on the data requirements for intravenous liposomal products developed with reference to an innovator liposomal product. (2013). https://www.ema.europa.eu/en/documents/scientific-guideline/reflection-paper-data-requirements-intravenous-liposomal-products-developed-reference-innovator_en.pdf
- US Food and Drug Administration. Draft guidance on amphotericin B (2020). www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_050740.pdf
- US Food and Drug Administration. Draft guidance on doxorubicin hydrochloride (NDA 050718 RV 09-2018).
- Lee JW , PetersenME, LinP, DresslerD, BekershyI. Quantitation of free and total amphotericin B in human biologic matrices by a liquid chromatography tandem mass spectrometric method. Ther. Drug Monit.23(3), 268–276 (2001).
- Egger P , BellmannR, WiedermannCJ. Determination of amphotericin B, liposomal B, and amphotericin B colloidal dispersion in plasma by high-performance liquid chromatography. J. Chromatogr. B760 (2), 307–313 (2001).
- Deshpande NM , GangradeMG, KekareMB, VaidyaVV. Determination of free and liposomal amphotericin B in human plasma by liquid chromatography-mass spectroscopy with solid phase extraction and protein precipitation techniques. J. Chromatogr. B878 (3-4), 315–326 (2010).
- Su C , YangH, SunH, FawcettJP, SunD, GuJ. Bioanalysis of free and liposomal amphotericin B in rat plasma using solid phase extraction and protein precipitation followed by LC–MS/MS. J. Pharma. Biomed. Anal.158, 288–293 (2018).
- Xie Y , ShaoN, JinYet al. Determination of non-liposomal and liposomal doxorubicin in plasma by LC–MS/MS coupled with an effective solid phase extraction: in comparison with ultrafiltration techniques and application to a pharmacokinetic study. J. Chromatogr. B1072, 149–160 (2018).
- Ji Y , ZhangX, LiuJet al. Direct quantitation of free, encapsulated, total doxorubicin and doxorubicinol in stabilized frozen human plasma to support a BE study of liposomal doxorubicin. J. Pharm. Biomed. Anal.189, 113388 (2020).
- Zhuang Q , LiuX, SunZ, WangH, JiangJ. A validated UPLC–MS/MS method to determine free and total irinotecan and its two metabolites in human plasma after intravenous administration of irinotecan hydrochloride liposome injection. J. Pharm. Biomed. Anal.170, 112–123 (2019).
- Yang W , YangZ, LiuJ, LiuD, WangY. The development of a method to quantify total and free irinotecan and 7-ethy-10-hydroxycamptothecin (SN-38) for pharmacokinetic and bio-distribution studies after administration of irinotecan liposomal formulation. Asian J. Pharm. Sci.14, 687–697 (2019).
- Chinese Pharmacopeia 9012 Guidance for Quantitative Bioanalytical Method Validation Guidelines (2015).
- US Food and Drug Administration, Center for Drug Evaluation and Research. US Food and Drug Administration Guidance for industry: bioanalytical method validation (2018). www.fda.gov/regulatory-information/search-fda-guidance-documents/bioanalytical-method-validation-guidance-industry
- European Medicines Agency. EMA guideline on bioanalytical method validation (2012). www.ema.europa.eu/en/documents/scientific-guideline/guideline-bioanalytical-method-validation_en.pdf
- European Medicines Agency. Draft ICH harmonised guideline M10 on bioanalytical method validation (2019). www.ema.europa.eu/en/documents/scientific-guideline/draft-ich-guideline-m10-bioanalytical-method-validation-step-2b_en.pdf
- Bulbake U , DoppalapudiS, KommineniN, KhanW. Liposomal formulation in clinical use: an updated review. Pharmaceutics9(12), 3–33 (2017).
- Bekersky I , FieldingRM, DresslerDE, LeeJW, BuellDN, WalshTJ. Plasma protein binding of amphotericin B and pharmacokinetics of bound versus unbound amphotericin B after administration of intravenous liposomal amphotericin B (AmBisome) and amphotericin B deoxycholate. Antimicrob. Agent. Chemother.46(3), 834–840 (2002).